Lancing Drug Reservoirs into Subcutaneous Fat to Combat Obesity and Associated Metabolic Diseases

Than, Aung; Duong, Phan Khanh; Zan, Ping; Liu, Junjie; Leow, Melvin Khee–Shing; Chen, Peng

doi:10.1002/smll.202002872

Cited by 9 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But BAT is scarce in adults. Intriguingly, brown-like beige adipocytes are inducible in WAT by certain activators through a browning process. − As WAT is a dynamic, modifiable, and metabolically active tissue, stimulating its ameliorating remodeling is an effective strategy to combat obesity and associated metabolic disorders.…”

Section: Introductionmentioning

confidence: 99%

Transdermal Photothermal-Pharmacotherapy to Remodel Adipose Tissue for Obesity and Metabolic Disorders

et al. 2022

Self Cite

View full text Add to dashboard Cite

Despite the increasing prevalence of obesity, the current medications, which act indirectly on the central nervous system to suppress appetite or on the gastrointestinal tract to inhibit fat absorption, suffer from poor effectiveness and side effects. Here, we developed a transdermal mild photothermal therapy directly acting on the root of evil (subcutaneous white adipose depot) to induce its ameliorating remodeling (browning, lipolysis, and apoptosis), based on the injectable thermoresponsive hydrogel encapsulated with copper sulfide nanodots. Further, combining pharmaceutical therapy with codelivery of mirabegron leads to a strong therapeutic synergy. This method not only ensures high effectiveness and low side effects due to localized and targeted application but also remotely creates significant improvements in systemic metabolism. Specifically, as compared to the untreated group, it totally inhibits obesity development in high-fat-diet fed mice (15% less in body weight) with decreased masses of both subcutaneous (40%) and visceral fats (54%), reduced serum levels of cholesterol (54%)/triglyceride (18%)/insulin (74%)/glucose (45%), and improved insulin sensitivity (65% less in insulin resistance index). This self-administrable method is amenable for long-term home-based treatment. Finally, multiple interconnected signaling pathways are revealed, providing mechanistic insights to develop effective strategies to combat obesity and associated metabolic disorders.

show abstract

Section: Introductionmentioning

confidence: 99%

Transdermal Photothermal-Pharmacotherapy to Remodel Adipose Tissue for Obesity and Metabolic Disorders

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Than et al developed core–shell structured micro-spear-like polymeric drug reservoirs, named micro-lances (MLs), using a simple hot-pressing method [ 131 ]. The core was based on PLGA and NaCl loaded with rosiglitazone and CL316243 (a selective β3-adrenergic receptor agonist), and the surface layer consisted of carboxymethylcellulose and Pluronic F68.…”

Section: Biomaterial-assisted Anti-obesity Therapymentioning

confidence: 99%

Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities

Duan

Liu

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Obesity is a global public health issue that results in many health complications or comorbidities, including type 2 diabetes mellitus, cardiovascular disease, and fatty liver. Pharmacotherapy alone or combined with either lifestyle alteration or surgery represents the main modality to combat obesity and its complications. However, most anti-obesity drugs are limited by their bioavailability, target specificity, and potential toxic effects. Only a handful of drugs, including orlistat, liraglutide, and semaglutide, are currently approved for clinical obesity treatment. Thus, there is an urgent need for alternative treatment strategies. Based on the new revelation of the pathogenesis of obesity and the efforts toward the multi-disciplinary integration of materials, chemistry, biotechnology, and pharmacy, some emerging obesity treatment strategies are gradually entering the field of preclinical and clinical research. Herein, by analyzing the current situation and challenges of various new obesity treatment strategies such as small-molecule drugs, natural drugs, and biotechnology drugs, the advanced functions and prospects of biomaterials in obesity-targeted delivery, as well as their biological activities and applications in obesity treatment, are systematically summarized. Finally, based on the systematic analysis of biomaterial-based obesity therapeutic strategies, the future prospects and challenges in this field are proposed.

show abstract

“…Table 4 lists some of the new anti-obesity agents being studied, as well as their possible mechanisms of action and their delivery methods. Hypodermic injection, transdermal [183,184] Thyroid hormone (T3) [185,186] ROSI Oral administration, transdermal [187,188] Curcumin [189,190] Fucoxanthin Oral administration [191] Bile acid [192] Capsaicin [193] Olive oil [194] GLP1 analogue Hypodermic injection [180] Resveratrol Oral administration [182] Gelatin Fat decomposition…”

Section: Development Of New Anti-obesity Drugsmentioning

confidence: 99%

Transdermal Drug Delivery Systems and Their Use in Obesity Treatment

Fang

2021

IJMS

View full text Add to dashboard Cite

Transdermal drug delivery (TDD) has recently emerged as an effective alternative to oral and injection administration because of its less invasiveness, low rejection rate, and excellent ease of administration. TDD has made an important contribution to medical practice such as diabetes, hemorrhoids, arthritis, migraine, and schizophrenia treatment, but has yet to fully achieve its potential in the treatment of obesity. Obesity has reached epidemic proportions globally and posed a significant threat to human health. Various approaches, including oral and injection administration have widely been used in clinical setting for obesity treatment. However, these traditional options remain ineffective and inconvenient, and carry risks of adverse effects. Therefore, alternative and advanced drug delivery strategies with higher efficacy and less toxicity such as TDD are urgently required for obesity treatment. This review summarizes current TDD technology, and the main anti-obesity drug delivery system. This review also provides insights into various anti-obesity drugs under study with a focus on the recent developments of TDD system for enhanced anti-obesity drug delivery. Although most of presented studies stay in animal stage, the application of TDD in anti-obesity drugs would have a significant impact on bringing safe and effective therapies to obese patients in the future.

show abstract

Lancing Drug Reservoirs into Subcutaneous Fat to Combat Obesity and Associated Metabolic Diseases

Cited by 9 publications

References 49 publications

Transdermal Photothermal-Pharmacotherapy to Remodel Adipose Tissue for Obesity and Metabolic Disorders

Transdermal Photothermal-Pharmacotherapy to Remodel Adipose Tissue for Obesity and Metabolic Disorders

Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities

Transdermal Drug Delivery Systems and Their Use in Obesity Treatment

Contact Info

Product

Resources

About